Is the priority review voucher program stimulating new drug development for tropical diseases?

Míreanna comhchosúla

• Correction to: Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development
  de réir: Catherine Mease, et al.
  Foilsithe / Cruthaithe: (2024-03-01)
• Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
  de réir: Kathleen L. Miller, et al.
  Foilsithe / Cruthaithe: (2021-06-01)
• Restructuring the FDA’s Food Program: Promises and Pitfalls
  de réir: Sammer Marzouk, et al.
  Foilsithe / Cruthaithe: (2024-10-01)
• New science, drug regulation, and emergent public health issues: The work of FDA’s division of applied regulatory science
  de réir: Kimberly Chiu, et al.
  Foilsithe / Cruthaithe: (2023-01-01)
• FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
  de réir: Kathleen L. Miller, et al.
  Foilsithe / Cruthaithe: (2020-09-01)